---
figid: PMC6614740__nihms-1038759-f0001
figlink: pmc/articles/PMC6614740/figure/F1/
number: 'Figure 1:'
caption: Simplified depiction of the RAS-RAF-MAPK signal transduction pathway. Binding
  of a ligand to a transmembrane receptor tyrosine kinase. Dimerization of receptor
  subunits leads to phosphorylation of cytoplasmic domains, leading to receuitment
  of adaptor proteins and guanine nucleotide exchange factors in turn leading to activation
  of RAS GTPase proteins, which activate RAF kinases (e.g. BRAF), in turn phosphorylating
  and activating MEK family kinases. MEK proteins can then phosphorylate ERK proteins,
  leading to ERK activation and translocation to the nucleus, where ERK serves to
  activate transcription factors, including c-myc, and regulate gene expression governing
  cell cycle entry and proliferation. PI3K is able to be activated directly via receptor
  tyrosine kinases following ligand binding and may additionally be activated by RAS
  proteins. Several commercially available and investigational inhibitors of BRAF,
  MEK1/2, and ERK1/2 are depicted as well.
pmcid: PMC6614740
papertitle: BRAF in the cross-hairs.
reftext: Mark B. Geyer, et al. Expert Rev Hematol. ;12(3):183-193.
pmc_ranked_result_index: '72734'
pathway_score: 0.9632844
filename: nihms-1038759-f0001.jpg
figtitle: Simplified depiction of the RAS-RAF-MAPK signal transduction pathway
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6614740__nihms-1038759-f0001.html
  '@type': Dataset
  description: Simplified depiction of the RAS-RAF-MAPK signal transduction pathway.
    Binding of a ligand to a transmembrane receptor tyrosine kinase. Dimerization
    of receptor subunits leads to phosphorylation of cytoplasmic domains, leading
    to receuitment of adaptor proteins and guanine nucleotide exchange factors in
    turn leading to activation of RAS GTPase proteins, which activate RAF kinases
    (e.g. BRAF), in turn phosphorylating and activating MEK family kinases. MEK proteins
    can then phosphorylate ERK proteins, leading to ERK activation and translocation
    to the nucleus, where ERK serves to activate transcription factors, including
    c-myc, and regulate gene expression governing cell cycle entry and proliferation.
    PI3K is able to be activated directly via receptor tyrosine kinases following
    ligand binding and may additionally be activated by RAS proteins. Several commercially
    available and investigational inhibitors of BRAF, MEK1/2, and ERK1/2 are depicted
    as well.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - HRAS
  - KRAS
  - NRAS
  - ARAF
  - BRAF
  - RAF1
  - AKT2
  - AKT3
  - AKT1
  - MK-8353
  - Trametinib
  - Vemurafenib
  - Cobimetinib
  - Dabrafenib
  - Encorafenib
  - Selumetinib
  - Binimetinib
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: МЕК1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK1/2)EMK-8353
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
chemicals:
- word: MK-8353
  source: MESH
  identifier: C042455
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Encorafenib
  source: ''
  identifier: ''
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Binimetinib
  source: MESH
  identifier: C581313
diseases: []
---
